World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
63
Citations
12172
World Ranking
3060
National Ranking
1434

Overview

Ronald P. Taylor is affiliated with the University of Virginia in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focus on Immunology, Genetics, Radiology, Nuclear Medicine and Imaging, Hematology, and Nephrology.

The scientist's recent publications cover various aspects of the complement system, immune responses, and therapies related to blood and kidney diseases. Notable papers include:

  • The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs (2020) published in Antibodies
  • The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference (2024) published in Kidney International
  • DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies (2020) published in Blood Cancer Journal
  • Phagocytosis via complement receptor 3 enables microbes to evade killing by neutrophils (2023) published in Journal of Leukocyte Biology
  • C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice (2020) published in JCI Insight

The scientist has published frequently in the following venues:

  • Blood
  • Antibodies
  • Journal of the American Society of Nephrology
  • Kidney International
  • Blood Cancer Journal

Research topics prominently addressed in their work include:

  • Complement system in diseases
  • Chronic Lymphocytic Leukemia Research
  • Monoclonal and Polyclonal Antibodies Research
  • Renal Diseases and Glomerulopathies
  • Blood groups and transfusion
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction

Frequent collaborators in their research are:

  • Margaret A. Lindorfer (10 joint publications)
  • Richard J. Smith (5 joint publications)
  • Gabriella R. Pitcher (4 joint publications)
  • Charles C. Chu (4 joint publications)
  • Jennifer E. Bruno (4 joint publications)

Best Publications

  • Complement is activated by IgG hexamers assembled at the cell surface.

    Christoph A. Diebolder;Christoph A. Diebolder;Frank J. Beurskens;Rob N. de Jong;Roman I. Koning

  • Mechanisms of killing by anti-CD20 monoclonal antibodies.

    Martin J. Glennie;Ruth R. French;Mark S. Cragg;Ronald P. Taylor

  • Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia

    Adam D. Kennedy;Paul V. Beum;Michael D. Solga;David J. DiLillo

  • Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

    G D Ross;W J Yount;M J Walport;J B Winfield

  • Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

    Andrew W. Pawluczkowycz;Frank J. Beurskens;Paul V. Beum;Margaret A. Lindorfer

  • The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes

    Paul V. Beum;Adam D. Kennedy;Michael E. Williams;Margaret A. Lindorfer

  • Physiological and pathological aspects of circulating immune complexes.

    Jürg A. Schifferli;Ronald P. Taylor

  • NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

    Siao Yi Wang;Emilian Racila;Ronald P. Taylor;George J. Weiner

  • Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia

    Michael E. Williams;John J. Densmore;Andrew W. Pawluczkowycz;Paul V. Beum

  • Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

    Ronald P Taylor;Margaret A Lindorfer

  • An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition and killing of CD20+ cells by Rituximab

    Adam D. Kennedy;Michael D. Solga;Theodore A. Schuman;Amos W. Chi

  • Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.

    Ronald P Taylor;Margaret A Lindorfer

  • Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

    Fabio Da Roit;Patrick J. Engelberts;Ronald P. Taylor;Esther C.W. Breij

  • Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.

    Ronald P. Taylor;Margaret A. Lindorfer

  • Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells

    Paul V. Beum;Elizabeth M. Peek;Margaret A. Lindorfer;Frank J. Beurskens

  • Influence of microbubble surface charge on capillary transit and myocardial contrast enhancement.

    Nicholas G Fisher;Jonathan P Christiansen;Alexander Klibanov;Ronald P Taylor

  • Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis

    Paul V. Beum;Margaret A. Lindorfer;Frank Beurskens;P. Todd Stukenberg

  • The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

    Antonio M. Risitano;Rosario Notaro;Caterina Pascariello;Michela Sica

  • Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

    Frank J. Beurskens;Margaret A. Lindorfer;Mohammed Farooqui;Paul V. Beum

  • Antibodies to sm in patients with systemic lupus erythematosus. correlation of sm antibody titers with disease activity and other laboratory parameters

    Franc A. Barada;Brian S. Andrews;John S. Davisiv;Ronald P. Taylor

  • Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes

    Paul V. Beum;David A. Mack;Andrew W. Pawluczkowycz;Margaret A. Lindorfer

Frequent Co-Authors

Margaret A. Lindorfer
Margaret A. Lindorfer University of Virginia
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Jan G. J. van de Winkel
Jan G. J. van de Winkel Genmab (United States)
Jeffrey C. Edberg
Jeffrey C. Edberg University of Alabama at Birmingham
V. Michael Holers
V. Michael Holers University of Colorado Denver
Tom Eirik Mollnes
Tom Eirik Mollnes Oslo University Hospital
John D. Lambris
John D. Lambris University of Pennsylvania
B. Paul Morgan
B. Paul Morgan Cardiff University
Gerald E. Marti
Gerald E. Marti National Institutes of Health
Dennis R. Burton
Dennis R. Burton Scripps Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise beyond Immunology, pursuing related healthcare degrees offers promising career pathways. Enrolling in accredited lpn programs easy to get into can be a practical first step for individuals seeking foundational clinical experience. These programs are designed to be accessible while maintaining high educational standards, making them ideal for fast-tracking entry into healthcare fields.

Advancing further, the easiest fnp program options provide a pathway for registered nurses aiming to specialize as Family Nurse Practitioners. These programs balance convenience and quality, offering flexible formats suitable for working professionals.

For those focusing on mental health, selecting from the best pmhnp programs online ensures access to strong clinical placement opportunities. This is crucial for gaining hands-on experience in psychiatric nursing, preparing graduates to make a meaningful impact in behavioral health care.

Cost is also a critical factor, which is why many prospective students prioritize the cheapest pmhnp programs. Affordable education options help reduce financial barriers while maintaining a quality curriculum tailored to psychiatric nurse practitioner careers.

Exploring these related degrees can complement an immunology background, broadening career opportunities across nursing and healthcare disciplines in the USA.

Best Scientists Citing Ronald P. Taylor

Trending Scientists

Recently Published Articles